$0.72
1.21% today
Nasdaq, Apr 02, 09:46 pm CET
ISIN
NL0010872420
Symbol
AFMD
Sector
Industry

Affimed N.V. Stock price

$0.71
-0.29 28.83% 1M
-2.60 78.55% 6M
-0.48 40.34% YTD
-5.64 88.82% 1Y
-46.19 98.49% 3Y
-15.19 95.54% 5Y
-61.59 98.86% 10Y
Nasdaq, Closing price Tue, Apr 01 2025
-0.01 1.84%
ISIN
NL0010872420
Symbol
AFMD
Sector
Industry

Key metrics

Market capitalization $10.81m
Enterprise Value $-1.71m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF 0.02
EV/Sales (TTM) EV/Sales -1.80
P/S ratio (TTM) P/S ratio 11.38
P/B ratio (TTM) P/B ratio 0.61
Revenue growth (TTM) Revenue growth -95.23%
Revenue (TTM) Revenue $950.00k
EBIT (operating result TTM) EBIT $-80.15m
Free Cash Flow (TTM) Free Cash Flow $-83.38m
Cash position $26.90m
EPS (TTM) EPS $-3.64
P/E forward negative
P/S forward 1.78
EV/Sales forward negative
Short interest 3.89%
Show more

Is Affimed N.V. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,807 stocks worldwide.

Affimed N.V. Stock Analysis

Unlock Scores for Free

Analyst Opinions

1 Analyst has issued a forecast Affimed N.V.:

1x Buy
100%

Analyst Opinions

1 Analyst has issued a forecast Affimed N.V.:

Buy
100%

Financial data from Affimed N.V.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
0.95 0.95
95% 95%
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 13 13
41% 41%
1,384%
- Research and Development Expense 61 61
48% 48%
6,372%
-76 -76
38% 38%
-8,046%
- Depreciation and Amortization 3.71 3.71
14% 14%
391%
EBIT (Operating Income) EBIT -80 -80
36% 36%
-8,437%
Net Profit -76 -76
40% 40%
-7,979%

In millions USD.

Don't miss a Thing! We will send you all news about Affimed N.V. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Affimed N.V. Stock News

Neutral
GlobeNewsWire
8 days ago
MANNHEIM, Germany, March 25, 2025 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today announced an abstract on AFM24 dose optimization using exposure response analysis has been accepted for presentation as a poster at the Annual Meeting of the American Association for Cancer Resea...
Neutral
GlobeNewsWire
about one month ago
MANNHEIM, Germany, March 03, 2025 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed”, or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced today that its Chief Executive Officer, Dr. Shawn Leland, PharmD, RPh, will participate in a fireside chat at the Leerink Partners Global Healthcare Conference 2...
Neutral
GlobeNewsWire
4 months ago
MANNHEIM, Germany, Dec. 09, 2024 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed”, or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today announced the oral presentation of data on AFM28 at the 66th ASH Annual Meeting and Exposition. The data, derived from the first-in-human Phase 1 study of AFM28, show...
More Affimed N.V. News

Company Profile

Affimed NV engages in discovering and developing of targeted cancer immunotherapies. Its pipelines include Innate Cell Engagers and T Cell Engagers. The company was founded in 2000 and is headquartered in Heidelberg, Germany.

Head office Netherlands
CEO Shawn Leland
Founded 2000
Website www.affimed.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today